Inviragen to commence HFMD vaccine Phase 1 trial
INV21 is a highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71 (EV71).
The study will evaluate the safety of INV21 along with immune responses in healthy adult volunteers aged 21 to 45 years.
Each adult volunteer will receive two immunizations separated by four weeks and will be monitored for any adverse reactions after each administration.
Immune responses to INV21 will be measured one, two and six months after the second immunization.
Inviragen's chief operating officer Joseph Santangelo said this first clinical study of INV21 is the result of years of research by Inviragen's scientists, and is an important milestone for the company.
"INV21 was developed in Singapore by Inviragen and our preclinical studies have demonstrated that this vaccine induces broad, neutralizing antibodies to multiple EV71 isolates," Santangelo said. GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity.
Clinical Trials For Healthy Volunteers - News
But each time a story such as this comes about, it brings to my mind that unending debate of ethics in such clinical trials. No, I'm not going into the technicalities of the greater good, the need of medicine etc. instead this is just to finally
The study will evaluate the safety of INV21 along with immune responses in healthy adult volunteers aged 21 to 45 years. Each adult volunteer will receive two immunizations separated by four weeks and will be monitored for any adverse reactions after
The Phase I clinical trial of VIA-3196 (ClinicalTrials.gov ID: NCT01367873) is an ascending single-dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of VIA-3196 in healthy subjects. The single-center trial will enroll
Ongoing clinical trials are testing agents like LSD, psilocybin, and mescaline to treat alcoholism and other addictions and to ease anxiety and depression in people who are dying of cancer. Though early results from small studies have been promising,
Orexo is planning to start and conclude the next clinical study in healthy volunteers in the fourth quarter of 2011. Orexo president and CEO Anders Lundstrom said OX27 has the potential to improve treatment of breakthrough pain in cancer patients.
Healthy Volunteer Study (12-54 years old) | West Coast Clinical Trials
Press Releases West Coast Clinical Trials Completes a thorough QT Trial with a complex exercise component
WCCT successfully completes a thorough QT cardiac safety study on schedule with a confinement period of 30 days with a [...]
West Coast Clinical Trials Completes CSF PK Sampling StudyWCCT recently completed its largest cerebrospinal cerebral spinal fluid (CSF) Pharmacokinetic (PK) sampling study. The typical CSF collection study has [...
Clinical Trials For Healthy Volunteers - Bookshelf
Clinical trials, what patients and healthy volunteers need to know
A vital resource for those who are considering enrolling in a clinical trial, or for the parents, friends, or relatives of those involved in a clinical trial, ...Statistical advances in the biomedical sciences, clinical trials, epidemiology, survival analysis, and bioinformatics
CHAPTER 1 Phase I Clinical Trials Anastasia Ivanova Department of Biostatistics, University of ... 1.2 PHASE I TRIALS IN HEALTHY VOLUNTEERS Buoen et al. ...Volunteers in research and testing
The survey asked if clinical trial protocols were reviewed by an external Ethics Committee. The questions concerning research studies in healthy volunteers ...Clinical trials in neurology
The critical role of phase I studies in oncology is covered in an article by the American Society of Clinical Oncology [10]. Healthy volunteer studies are ...Clinical trials in Belgium, the implementation of the European Clinical Trials Directive 2001/20/EC into the Belgian law of May 7, 2004 concerning experiments on the human person ; operational guidance
SPECIFIC PROTECTION FOR SUBJECTS PARTICIPATING IN PHASE I CLINICAL TRIALS 61. In order to protect healthy volunteers from participating in too many ...Everyday Articles Directory
Clinical Trials for Healthy Volunteers in the United Kingdom - UK
Clinical Trials for Healthy Volunteers in the United Kingdom. Paid clinical trial volunteers wanted in the UK. Paidclinicaltrials.org is a comprehensive registry of ...
Clinical Study Volunteers for Healthy & Pre-Existing ...
Learn about clinical study volunteer opportunities at PPD for healthy volunteers or patients with pre-existing conditions. Trials conducted by doctors & scientists.
Clinical Trials: Healthy Volunteers
Many clinical research studies need healthy volunteers to participate ... Healthy volunteers who choose to participate in a clinical trial may help advance medical ...
Clinical Trials: Healthy Volunteers -
The trial posting for Assessment of post-resection remote memory deficits in adults with ... Browse Clinical Trials by Therapeutic Area. Healthy Volunteers (144) ...
NIH Clinical Center: Healthy Volunteer Program
Healthy volunteers provide researchers with important information for comparison with ... Healthy volunteers who take part in clinical research studies at NIH may: ...